<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976465</url>
  </required_header>
  <id_info>
    <org_study_id>SLE with Pregnancy QiluH</org_study_id>
    <nct_id>NCT04976465</nct_id>
  </id_info>
  <brief_title>Treatment and Clinical Outcomes Among SLE Patients in Pregnancy</brief_title>
  <official_title>Treatment and Clinical Outcomes Among SLE Patients in Pregnancy: A Real World Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic lupus erythematosus (SLE) is a kind of systemic autoimmune disease which can cause&#xD;
      multiple organs and system damage, which often occurs in women of childbearing age. Compared&#xD;
      with healthy pregnant women, SLE patients have higher incidence of premature delivery,&#xD;
      preeclampsia and fetal loss during pregnancy. Since SLE patients usually have disease&#xD;
      activity during pregnancy and postpartum, and a variety of maternal and fetal diseases are&#xD;
      closely related to SLE, it is very important to monitor the disease activity and drug&#xD;
      treatment of SLE patients during pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To study the risk factors of poor pregnancy outcomes in SLE patients, and evaluate&#xD;
      impact of different therapies on the maternal and fetal health. Methods: Our department and&#xD;
      Shanghai Gothic Network Technology Co., Ltd. jointly established the chronic disease&#xD;
      management of SLE patients during pregnancy and lactation by using Smart System of Disease&#xD;
      Management#SSDM#. With this platform#patients in pregnancy can consult with rheumatologists&#xD;
      face to face and follow-up regularly.&#xD;
&#xD;
      Follow-up: Consultation and followup will be scheduled every 4 weeks from confirmed pregnancy&#xD;
      until delivery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>After 28 weeks of gestation]</time_frame>
    <description>Percentage of all patients that lead to live birth after 28 weeks of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early miscarriage</measure>
    <time_frame>within 10 weeks of gestation]</time_frame>
    <description>Spontaneous pregnancy loss within 10 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine deaths</measure>
    <time_frame>after 10 weeks of gestation</time_frame>
    <description>Spontaneous pregnancy loss after 10 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stillbirth</measure>
    <time_frame>after 20 weeks of gestation</time_frame>
    <description>Spontaneous pregnancy loss after 20 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine growth retardation (IUGR)</measure>
    <time_frame>between 28 and 37 weeks of gestation</time_frame>
    <description>weight below the 10th percentile for the gestational age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with low amniotic fluid during pregnancy</measure>
    <time_frame>during pregnancy#an average of 10 months</time_frame>
    <description>the number of participants whose B-ultrasound indicates low amniotic fluid during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal S / D values during pregnancy</measure>
    <time_frame>during pregnancy#an average of 10 months</time_frame>
    <description>the number of participants whose B-ultrasound indicates abnormal S / D values during pregnancy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>combined with aPL(+)</arm_group_label>
    <description>the antiphospholipid antibodies appear in blood at least once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combined with aPL(-)</arm_group_label>
    <description>the antiphospholipid antibodies never appear in blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulation</intervention_name>
    <description>Drug:&#xD;
Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred&#xD;
Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.&#xD;
Other Names: HCQ&#xD;
Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.&#xD;
Other Names: Asp&#xD;
Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.&#xD;
Other Names: LMWH</description>
    <arm_group_label>combined with aPL(+)</arm_group_label>
    <arm_group_label>combined with aPL(-)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Without Anticoagulation</intervention_name>
    <description>Drug:&#xD;
Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred&#xD;
Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.&#xD;
Other Names: HCQ</description>
    <arm_group_label>combined with aPL(+)</arm_group_label>
    <arm_group_label>combined with aPL(-)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        female with pregnance in accordance with the diagnostic criteria of SLE&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with systemic lupus erythematosus (SLE) (ACR criteria, 1997);&#xD;
&#xD;
          2. Pregnant women aged 20-45 years old;&#xD;
&#xD;
          3. Willing to participate in this study, willing to medication and follow-up according to&#xD;
             the treatment plan, and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The cause of previous abortion was known:&#xD;
&#xD;
               -  Known chromosomal abnormalities in the parent, maternal or embryo.&#xD;
&#xD;
                  - Page 3 of 4 [DRAFT] -• Endocrine dysfunction of pregnant women: luteal&#xD;
                  dysfunction; Polycystic ovarian syndrome; Ovarian premature failure (FSH&#xD;
&#xD;
                  ≥ 20uu/ L) in follicular stage;&#xD;
&#xD;
               -  Hyperprolactinemia thyroid disease; Other hypothalamic pituitary adrenal axis&#xD;
                  abnormalities in diabetes mellitus.&#xD;
&#xD;
               -  Abnormal anatomy of pregnant women: abnormal uterus; Asherman syndrome; The&#xD;
                  uterine fibrosis of cervical insufficiency is more than 5 cm. Vaginal infection.&#xD;
&#xD;
               -  Any known serious heart disease, liver, kidney, blood or endocrine disease.&#xD;
&#xD;
          2. Any active infection Active viral hepatitis includes hepatitis B virus (HBV),&#xD;
             hepatitis C virus (HCV), human papillomavirus (HPV). Active infections include small&#xD;
             intestine herpes zoster virus (VZV), human immunodeficiency virus (HIV), syphilis or&#xD;
             tuberculosis.&#xD;
&#xD;
          3. Allergic to prednisone, hydroxychloroquine, low molecular weight heparin or aspirin.&#xD;
&#xD;
          4. The history of the disease is as follows:&#xD;
&#xD;
               -  There was a history of peptic ulcer or upper gastrointestinal bleeding in the&#xD;
                  past.&#xD;
&#xD;
               -  The past history of malignant tumor.&#xD;
&#xD;
               -  The past history of epilepsy or psychosis.&#xD;
&#xD;
          5. Women who disagree or cannot complete the follow-up during pregnancy and after&#xD;
             delivery.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoyun Yang, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiang Shu, Dr.</last_name>
    <phone>0086-0531-82169654</phone>
    <email>shuqiang@sdu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yunfei Guo, Bachelor</last_name>
    <phone>0086-0531-82169654</phone>
    <email>guoyunfei@mail.sdu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qilu Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyun Yang, Dr</last_name>
      <phone>0086-0531-82169166</phone>
      <email>qlyykyc@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Qiang Shu</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Pregnancy Related</keyword>
  <keyword>clinical features</keyword>
  <keyword>Risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

